FDA Investigator Deborah B Nixon

Deborah B Nixon has inspections in 4 countries as of 27 Sep 2023. Deborah B Nixon has collaborated with a combinined 2518 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
68
Last Inspection Date:
27 Sep 2023
Investigator Role:
FDA Investigator
Redica ID:
100007022
Country:
United States of America, Peru, Canada, Spain
Co-Investigator(s):
Addam S Reynolds, Alberto A Viciedo, Allen Lou, Amatul H Marium, Amy Kim, Amy L Singer, Amy M Cramer, Amy W Yan Mai, Ana S Cabrera, Ann Marie Montemurro, Annemarie Bodnar, Anthony J Donato, Anthony M Criscuolo, Jr, Atul J Agrawal, Barbara J Maulfair, Barbara J Wilimczyk, Barbara Jwilimczyk Macri, Barbara L Rellahan, PhD, Byungja E Marciante, Cara M Minelli, Charles J Chacko, Cheryl A Grandinetti, Christina N Maurino, Craig W Swanson, Cynthia A Harris, MD, RN, Daniel J Grabicki, David H Smith, Dawn L Wydner, Demitria J Xiradakis, Denise M Visco, Investigator, Dennis E Guilfoyle, PhD, Doreen P Gubbay, Douglas C Kovacs, Dr. Gopa Biswas, PhD, Dr. Zhou Chen (nmi), MD PhD, Emest F Bizjak, Emily A Walters, Emmanuel J Ramos, Eric J Cunningham, Eric Rothschild, Erin D Mccaffery, Frank J Marciniak, Frederick Razzaghi, George Pyramides, Gianine E Tompkins, Guerlain Ulysse, Helen B Ricalde, Helen Verdel, Herrmann, Jacqueline Mdiaz Albertini, Jean Blackston Hill, Jean M Kelahan, Jennifer A Bazergui, Jennifer L Custodio, Jennifer Macmillan, Jessica M Monteiro, Joan A Loreng, Jonee J Mearns, Jose M Cayuela, Joseph F Mcginnis, RPh, Joy Rkozlowski Klena, Karen E D'orazio, Kassa Ayalew, MD, Kathleen B Swat, Keith M Reilly, Kelli F Dobilas, Kerry A Kurdilla, Kevin Obrien, King, Kinh Q Mac, Kristy A Zielny, Krystal O Ogunremi, Lata C Mathew, PhD, Lawrence R Johnson, Li Li, Liatte Kreuger, PharmD, Lisa Harlan, Lisa Mathew, Luella J Rossi, Margaret M Sands, Maria Estrella, Marjorie D Schultz, Matthew A Spataro, Matthew W Kyle, Mayar M Mussa, Melba T Rivera, Melba Trivera Clavell, Melissa A Freeman, Melissa A Zuppe, Melissa B Libby, Melissa T Roy, Michael F Skelly, PhD, Michael R Klapal, Michael Serrano, Michele Gottshall, Miguel G Manzano, Miguel Gmanzano Maldonado, Nancy F Scheraga, Nancy L Rolli, Niketa Patel, Nikki S Ramirez, Nilufer Tampal, PhD, Nina Yang, Niraj Mehta, Paul L Bellamy, Peter R Lenahan, Prabhu P Raju, Rabin N Ghoshal, Regina T Brown, Robert G Ruff, Robert J Maffei, Robert W Jennings, Rodney T Allnutt, Roger J Adams, Sandra Kershaw, Sarah Adella Fave, Sarah Forney, Schultz, Sherri J Liu, Shirley H Isbill, Shirley S Wen, Sidney B Priesmeyer, Simone E Pitts, Sinai Davis, State Agency, Stephanie T Durso, Stephen J Mottola, Susan M Halsted, Tania E Garcia, Tania E Vizcaino, Tara G Bizjak, Tara R Gooen, Teena H Aiken, Thomas J Arista, Tonia F Bernard, Tyanna N Hadley, Tynna N Hadley, Valerie C Reed, Valerie Reed, Victoria Spivak, Wayne J Meyer, Xikui Chen (nmi), PhD, Yvesna C Blaise

Deborah B Nixon's Documents

Publish Date Document Type Title
October, 2003 EIR Hackensack Meridian Health IRB - EIR, 2003-10-30
April, 2003 FDA 483 Hoffmann La Roche Inc - Form 483, 2003-04-30
September, 2003 FDA 483 Response Valley Hospital IRB - Form 483R, 2003-09-12
February, 2005 EIR SGS North America Inc. - EIR, 2005-02-07
September, 2002 FDA 483 Response J&J Pharmaceutical Research & Development, L.L.C. - Form 483R, 2002-09-20
February, 2003 FDA 483 Novartis Pharmaceuticals Corporation - Form 483, 2003-02-10
September, 2003 EIR Valley Hospital IRB - EIR, 2003-09-05
June, 2006 FDA 483 Merck & Co., Inc. - Form 483, 2006-06-23
September, 2003 FDA 483 Consumer Product Testing Company, Inc - Form 483, 2003-09-26
October, 2003 FDA 483 Hackensack Meridian Health IRB - Form 483, 2003-10-30
April, 2003 EIR Hoffmann La Roche Inc - EIR, 2003-04-30
October, 2007 FDA 483 Merck Sharp & Dohme - Form 483, 2007-10-05
December, 2003 EIR Merck & Co., Inc. - EIR, 2003-12-05
September, 2003 FDA 483 Valley Hospital IRB - Form 483, 2003-09-05
December, 2006 FDA 483 Schering Corporation - Form 483, 2006-12-20
February, 2003 FDA 483 Response Novartis Pharmaceuticals Corporation - Form 483R, 2003-02-21
August, 2004 EIR Scott D. Rowley, M.D. - EIR, 2004-08-12
September, 2002 EIR J&J Pharmaceutical Research & Development, L.L.C. - EIR, 2002-09-13
July, 2003 EIR SGS North America Inc. - EIR, 2003-07-03
February, 2005 FDA 483 Response SGS North America Inc. - Form 483R, 2005-03-03
September, 2003 EIR Consumer Product Testing Company, Inc - EIR, 2003-09-26
September, 2003 FDA 483 Response Consumer Product Testing Company, Inc - Form 483R, 2003-10-09
February, 2005 FDA 483 SGS North America Inc. - Form 483, 2005-02-07
September, 2002 FDA 483 J&J Pharmaceutical Research & Development, L.L.C. - Form 483, 2002-09-13
July, 2003 FDA 483 Response SGS North America Inc. - Form 483R, 2003-07-25
December, 2004 FDA 483 Hackensack University Medical Center - Form 483, 2004-12-15
May, 2008 FDA 483 Hoffmann La Roche Inc - Form 483, 2008-05-22
May, 2008 EIR Hoffmann La Roche Inc - EIR, 2008-05-22
August, 2004 FDA 483 Scott D. Rowley, M.D. - Form 483, 2004-08-12
July, 2003 FDA 483 SGS North America Inc. - Form 483, 2003-07-03
February, 2004 FDA 483 Cordis Corporation - Form 483, 2004-03-03
February, 2003 EIR Novartis Pharmaceuticals Corporation - EIR, 2003-02-10
October, 2003 FDA 483 Response Hackensack Meridian Health IRB - Form 483R, 2003-11-04
April, 2003 FDA 483 Response Hoffmann La Roche Inc - Form 483R, 2003-05-07

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more